A Study to Evaluate the Palatability of a Nutritional Support Biscuit (Fitabisc) (Fitabisc)

• ClinicalTrials.gov Identifier: NCT03859661
• Recruitment Status: Terminated
• First Posted: March 1, 2019
• Last Update Posted: March 1, 2019
• Sponsor: York Teaching Hospitals NHS Foundation Trust
• Information provided by (Responsible Party): York Teaching Hospitals NHS Foundation Trust

Study Description

Brief Summary:

A study to evaluate the palatability of a nutritional support biscuit (Fitabisc) in patients about to undergo colorectal surgery.

Condition or disease	Intervention/treatment	Phase
Colorectal Surgery	Dietary Supplement: Fitabisc	Not Applicable

Detailed Description:

The question of preoperative supplementation raises another issue about how this might be provided for patients, especially at home.

The Chief Investigator has formulated a new biscuit 'Fitabisc' that contains the key antioxidants; vitamins C and E, selenium and glutamine. The advantage of a biscuit is that all ingredients of interest are combined within the one item and so this may be easier for patients to 'take' than other types of supplement. A survey involving 17 community pharmacies in England and Northern Ireland found that 60% of patients aged 60 - 89 years had difficulty swallowing tablets and capsules. The consistency of the biscuit is softer than traditional shortbread and crumbs readily which we hope will make it easy to eat.

The aim of this study is to test the palatability of Fitabisc and whether patients undergoing abdominal surgery can eat it in the desired quantities for 10 days before they are admitted to hospital.

In summary, most studies to date have looked perioperative or postoperative supplementation with antioxidants alone. No attempt has been made to do this using a palatable biscuit that would facilitate preoperative oral supplementation. If this study confirms the palatability of the biscuit and there is adherence to eating it then it would be our intention to set up a prospective randomized study in which the potential efficacy of Fitabisc would be evaluated.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 10 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: A Study to Evaluate the Palatability of a Nutritional Support Biscuit (Fitabisc)
• Study Start Date: December 2015
• Actual Primary Completion Date: September 11, 2017
• Actual Study Completion Date: September 11, 2017

Arms and Interventions

Intervention Details:

• Dietary Supplement: Fitabisc
  Fitabisc is a chocolate cookie with vanilla cream filling which contains the most important antioxidants Vitamin C, Vitamin E, and the mineral Selenium. Fitabisc is not commercially available and for the purposes of this study it will be manufactured by Calerrific Ltd, which already produces a biscuit called CalBisc 100 as a simple calorie and nutritional supplement. Production takes place in a BRC Global Standard Grade A certified bakery operated by Farringford Foods in Portadown, Northern Ireland.

Outcome Measures

Primary Outcome Measures :

1. Adherence to dose [ Time Frame: 10 days ]
   Patients to keep a diary of their consumption
2. Palatability of biscuit [ Time Frame: 10 days ]
   Study will measure palatability on a standard Likert scale after 10 days

Secondary Outcome Measures :

1. Progress of patients following surgery [ Time Frame: 4-6 weeks post op. ]
   Adverse event collection - via patient reported outcomes and review of patient notes following surgery
2. Collection of events that might be associated with the ingredients of the biscuit. [ Time Frame: 4-6 weeks post op. ]
   Adverse event collection - via patient reported outcomes and review of patient notes following surgery

Eligibility Criteria

• Ages Eligible for Study: 16 Years to 80 Years (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients between the ages of 16 and 80 years inclusive.
• Patients who are having colorectal surgery.
• Patients who are able to give voluntary, written informed consent to participate in the study and from whom written consent has been obtained.

Exclusion Criteria:

• Those who cannot or do not provide informed consent
• Patients with a known or suspected allergy to any of the ingredients of Fitabisc e.g. gluten or dairy products

• Patients with one of the following co-morbidities:

  • Haemochromatosis
  • Thalassaemia
  • Kidney disease
  • Liver disease
  • Reye syndrome
• Patients who already take supplements of vitamin C, E, selenium or glutamine.
• Patients with type 1 diabetes, or type 2 diabetes that requires them to have insulin or a hypoglycaemic drug such as Metformin.

Contacts and Locations

Locations

United Kingdom

York Teaching Hospital NHS Foundation Trust

York, United Kingdom, YO31 8HE

Sponsors and Collaborators

York Teaching Hospitals NHS Foundation Trust

Investigators

• Principal Investigator: John Macfie, MBChB, MD; York Teaching Hospital NHS Foundation Trust

More Information

• Responsible Party: York Teaching Hospitals NHS Foundation Trust
• ClinicalTrials.gov Identifier: NCT03859661
• Other Study ID Numbers: SNE2445
• First Posted: March 1, 2019
• Last Update Posted: March 1, 2019
• Last Verified: February 2019